Comparing Octreotide vs Sandostatin LAR Depot
| Octreotide | Sandostatin LAR Depot (octreotide) |
|
|---|
| Octreotide | Sandostatin LAR Depot (octreotide) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Diarrhea, Diabetes - Type 1, Dumping Syndrome, Gastrinoma, Glucagonoma, Insulinoma, Pituitary Adenoma, Postural Orthostatic Tachycardia Syndrome, Small... View more |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin LAR Depot may also be used for purposes not listed in this medication guide. |
Related suggestions Carcinoid Tumor
Vasoactive Intestinal Peptide Tumor
Popular comparisons
|
|||||||||||||||
| More about Octreotide | More about Sandostatin LAR Depot (octreotide) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Octreotide has an average rating of 7.7 out of 10 from a total of 18 ratings on Drugs.com. 72% of reviewers reported a positive effect, while 11% reported a negative effect. |
Sandostatin LAR Depot has an average rating of 8.7 out of 10 from a total of 7 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Octreotide side effects |
View all Sandostatin LAR Depot side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
Lower cost generic |
Lower cost generic approved | ||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Octreotide prices |
View all Sandostatin LAR Depot prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin LAR Depot | Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
1.5 hours |
1.5 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 164 drugs are known to interact with Octreotide:
|
A total of 164 drugs are known to interact with Sandostatin LAR Depot:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
|
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
June 26, 2020 |
N/A |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.